Article

Another application: Lens approved for therapy; CIBA helps fire victims

Atlanta-CIBA Vision's Focus Night & Day 30-day contact lenses will be marketed throughout Europe after receiving the CE Mark for therapeutic use.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Related Content
Ocugen’s OCU410ST receives Rare Pediatric Disease Designation for the treatment of ABCA4-associated retinopathies
May 27th 2025

Ocugen’s OCU410ST receives Rare Pediatric Disease Designation for the treatment of ABCA4-associated retinopathies

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

(Image credit: AdobeStock/frender) Q&A: Brandon D. Ayres, MD, on streamlining anterior vitrectomy with a high-speed, small-gauge probe at ASCRS 2025
May 26th 2025

Q&A: Brandon D. Ayres, MD, on streamlining anterior vitrectomy with a high-speed, small-gauge probe at ASCRS 2025

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Bridging disciplines and elevating care: A Q&A with John Gelles, OD, and Steven Greenstein, MD
May 25th 2025

Bridging disciplines and elevating care: A Q&A with John Gelles, OD, and Steven Greenstein, MD

Metabolomic profiling of vitreous humor reveals stage-specific biomarkers in diabetic retinopathy
May 25th 2025

Metabolomic profiling of vitreous humor reveals stage-specific biomarkers in diabetic retinopathy

© 2025 MJH Life Sciences

All rights reserved.